Implanet (ALIMP.PA) Stock Price
Implanet Price
Revenue has compounded at 9.3% per year over the past 14 years to 9.41 M EUR. Implanet's net margin stands at -46.4%, up from -102.2% several years earlier. Analysts set a median price target of 2.00 EUR, implying 1,071.9% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.
Implanet stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Implanet over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Implanet stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Implanet's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Implanet Price |
|---|---|
| 9/9/2026 | 0.17 EUR |
| 9/8/2026 | 0.17 EUR |
| 9/7/2026 | 0.17 EUR |
| 9/4/2026 | 0.18 EUR |
| 9/3/2026 | 0.18 EUR |
| 9/2/2026 | 0.17 EUR |
| 9/1/2026 | 0.18 EUR |
| 8/31/2026 | 0.18 EUR |
| 8/28/2026 | 0.18 EUR |
| 8/27/2026 | 0.19 EUR |
| 8/26/2026 | 0.19 EUR |
| 8/25/2026 | 0.19 EUR |
| 8/24/2026 | 0.18 EUR |
| 8/21/2026 | 0.18 EUR |
| 8/20/2026 | 0.19 EUR |
| 8/19/2026 | 0.18 EUR |
| 8/18/2026 | 0.18 EUR |
| 8/17/2026 | 0.19 EUR |
| 8/14/2026 | 0.18 EUR |
| 8/13/2026 | 0.18 EUR |
| 8/12/2026 | 0.18 EUR |
| 8/11/2026 | 0.17 EUR |
| 8/10/2026 | 0.18 EUR |
| 8/7/2026 | 0.18 EUR |
| 8/6/2026 | 0.17 EUR |
| 8/5/2026 | 0.17 EUR |
| 8/4/2026 | 0.17 EUR |
| 7/31/2026 | 0.16 EUR |
| 7/30/2026 | 0.17 EUR |
| 7/29/2026 | 0.17 EUR |
Implanet Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Implanet Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | 4.00 | 6.00 | 6.00 | 7.00 | 6.00 | 7.00 | 7.00 | 6.00 | 7.00 | 3.00 | 6.00 | 8.00 | 7.00 | 9.00 | 20.00 |
| – | 100.00 | 50.00 | – | 16.67 | -14.29 | 16.67 | – | -14.29 | 16.67 | -57.14 | 100.00 | 33.33 | -12.50 | 28.57 | 122.22 |
| 50.00 | 25.00 | 33.33 | 33.33 | 28.57 | 33.33 | 42.86 | 42.86 | 50.00 | 57.14 | 66.67 | 50.00 | 50.00 | 57.14 | 44.44 | 44.44 |
| 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 2.00 | 3.00 | 4.00 | 4.00 | 4.00 | 8.89 |
| -4.00 | -6.00 | -4.00 | -6.00 | -6.00 | -7.00 | -6.00 | -6.00 | -5.00 | -3.00 | -3.00 | -4.00 | -3.00 | -4.00 | -4.00 | – |
| -200.00 | -150.00 | -66.67 | -100.00 | -85.71 | -116.67 | -85.71 | -85.71 | -83.33 | -42.86 | -100.00 | -66.67 | -37.50 | -57.14 | -44.44 | – |
| -6.00 | -3.00 | -4.00 | -6.00 | -6.00 | -8.00 | -7.00 | -6.00 | -5.00 | -3.00 | -3.00 | -3.00 | -3.00 | -6.00 | -4.00 | – |
| – | -50.00 | 33.33 | 50.00 | – | 33.33 | -12.50 | -14.29 | -16.67 | -40.00 | – | – | – | 100.00 | -33.33 | – |
| 31.37 | 38.64 | 41.99 | 4.54 | 0.19 | 0.30 | 0.46 | 0.58 | 0.75 | 1.71 | 3.07 | 8.51 | 21.03 | 39.87 | 118.13 | 118.13 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Implanet generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Implanet retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Implanet's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Implanet has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Implanet's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Implanet stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Implanet Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Implanet business model & stock analysis
Implanet SWOT Analysis
Strengths
Implanet SA possesses several strengths that contribute to its success in the market:
- Advanced medical technology: Implanet SA utilizes cutting-edge technology in developing its medical devices, providing it with a competitive advantage.
- Strong research and development capabilities: The company invests heavily in R&D, enabling it to innovate and develop new products to meet market demands.
- Established brand reputation: Implanet SA has built a strong brand image and is recognized for its quality and reliability in the medical industry.
- Global presence: The company has a widespread global presence, allowing it to target diverse markets and customer bases.
Weaknesses
Despite its strengths, Implanet SA also faces certain weaknesses that can hinder its growth:
- Limited product portfolio: The company's product range is relatively limited, which may restrict its ability to cater to varied customer needs.
- High dependency on key customers: Implanet SA relies heavily on a few major customers, making it vulnerable to the loss of any significant contracts.
- Financial constraints: The company may face financial challenges in funding its expansion plans and sustaining its operations.
- Regulatory compliance: Compliance with stringent regulations in the medical industry can pose challenges and increase operational costs for Implanet SA.
Opportunities
Implanet SA can leverage various opportunities to enhance its business prospects:
- Market expansion: There is a growing demand for advanced medical devices, particularly in emerging markets, providing Implanet SA with opportunities to penetrate new geographies.
- Product diversification: The company can explore diversifying its product range to cater to a wider customer base and capitalize on emerging technologies.
- Strategic partnerships: Collaborating with other industry players or healthcare institutions can enable Implanet SA to enhance its market reach and develop innovative solutions.
- Changing demographics: The aging population and increasing healthcare needs create a favorable environment for Implanet SA to target a larger patient base.
Threats
Implanet SA faces several threats that may impact its business operations:
- Intense competition: The medical device industry is highly competitive, with the presence of established players and new entrants vying for market share.
- Technological advancements: Rapid technological advancements can make existing products obsolete and pose challenges for Implanet SA to stay ahead in the market.
- Economic fluctuations: Economic uncertainties and downturns can impact healthcare spending, potentially affecting the demand for Implanet SA's products.
- Regulatory changes: Frequent changes in healthcare regulations can impact the approval process, time to market, and overall compliance costs for Implanet SA.
Implanet Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Implanet historical P/E ratio, EBIT multiple, and P/S ratio
Implanet annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Implanet shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Implanet stock splits
Current Implanet forecasts and price targets in September 2026
Analyst Price Targets 2026Implanet shareholder structure
| % | Name |
|---|---|
78.87675% | |
0.72315% | |
0.00365% |
Implanet Executives and Management Board
5 members · 20 % women
Mr. Ludovic Lastennet
Chief Executive Officer, Director, Commercial Director · since 2013
294,000.00 EUR
Management
Mr. Benjamin Letienne
Vice President of Marketing & International Sales, Director · since 2021
Board of Directors
Mr. Mingyan Liu
Chairman of the Board
Mr. David Fan
Director
Ms. Nuan Ni
Director
Frequently asked questions about Implanet
The business model of Implanet SA focuses on providing innovative and advanced medical devices for orthopedic surgery. Implanet specializes in developing and marketing implant solutions for spinal surgery, enabling healthcare professionals to offer better patient care. Implanet SA's business model is centered around delivering cutting-edge technologies and solutions that improve surgical outcomes, enhance patient comfort, and reduce post-operative complications. The company's dedication to research, development, and collaboration with healthcare experts ensures the continuous advancement of implantable medical devices, making Implanet SA a key player in the orthopedic industry.
Implanet SA is primarily active in the medical device industry. With a focus on innovative implant technologies, Implanet SA specializes in providing solutions for spinal surgery. The company's expertise lies in the development, manufacturing, and distribution of implantable medical devices that aim to improve patient outcomes. As a key player in the healthcare sector, Implanet SA combines advanced research, cutting-edge technologies, and a commitment to delivering high-quality products. With its focus on the medical device industry, Implanet SA is dedicated to revolutionizing the field of spinal surgery and enhancing the lives of patients worldwide.
The main competitors of Implanet SA in the market include companies like Medtronic, Stryker Corporation, Johnson & Johnson, and Zimmer Biomet Holdings.
Implanet SA is a renowned medical device company that specializes in developing innovative solutions for orthopedic surgery. Founded in 2007, Implanet SA has quickly gained prominence for its pioneering products such as JAZZ implants and innovative surgical techniques. With a strong focus on spinal surgery, Implanet SA has established itself as a global leader in providing clinicians with advanced tools to improve patient outcomes. The company's dedication to research and development, along with strategic partnerships with key players in the industry, has catapulted Implanet SA to the forefront of the orthopedic market. Guided by a mission to enhance the lives of patients, Implanet SA continues to push boundaries and revolutionize the field of orthopedics.
Implanet SA, a leading medical technology company, has achieved several significant milestones. Firstly, the company successfully received CE Mark approval for its flagship product, JAZZ. This breakthrough allowed Implanet SA to commercialize and distribute its innovative spinal implant system throughout Europe. Additionally, Implanet SA secured FDA 510(k) clearance, enabling JAZZ's market access in the United States. The company's global expansion has continued with successful product launches in several countries, including Japan and Australia. Implanet SA's commitment to innovation and its dedication to improving patient outcomes have resulted in these notable achievements, solidifying its position as a premier player in the medical technology industry.
Implanet SA is primarily present in various countries and regions. The company operates mainly in the United States, Europe, and Asia. In the United States, Implanet SA has established a strong presence in the orthopedic and spine markets, providing innovative solutions for healthcare professionals. In Europe, it has a significant presence in France, Germany, Italy, Spain, and the United Kingdom, among others. In Asia, Implanet SA has expanded its business operations in key markets like China and Japan. With its global reach, Implanet SA continues to expand and serve a wide range of customers in different parts of the world.
Implanet SA is a leading medical device company that focuses on the development and commercialization of innovative orthopedic solutions. With a strong commitment to patient care and satisfaction, Implanet SA emphasizes values such as integrity, excellence, and collaboration. The company's corporate philosophy revolves around dedicated research and development efforts to provide cutting-edge implants and instruments for spinal surgery. Implanet SA's mission is to improve patients' quality of life by offering state-of-the-art products that contribute to better spinal health and mobility. Through their visionary approach and dedication to advancing orthopedic technologies, Implanet SA continues to be a trusted name in the field of spinal surgery.
Analysts currently set an average price target of 2.00 EUR for the Implanet stock (median: 2.00 EUR), implying +1,071.9 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Implanet stock: 8 recommend buying, 1 holding and 0 selling.
The Implanet share (ALIMP.PA) is listed on 3 stock exchanges, including: Frankfurt (IM11.F), Paris (ALIMP.PA).
Implanet SA is a French medical technology company that specializes in the development and distribution of medical implants and instruments for the treatment of vertebral fractures and back pain. The company offers a wide range of solutions for the specific needs of patients, physicians, and facilities. Implanet's business model is designed to provide a comprehensive solution for the treatment of spinal diseases. The company offers a complete range of medical products and services tailored to the needs of patients, physicians, and facilities. Implanet manufactures and distributes innovative medical implants and instruments designed to provide better accuracy and effectiveness in the treatment of vertebral fractures, spinal deformities, and other spine-related conditions. The offered products include the Jazz system for bone and soft tissue reinforcement, the JAZZ Cap implant for improving quality of life in mild to moderate spinal diseases, and the JAZZ Lock implant for support in difficult cases. In addition, Implanet also offers a wide range of services including education, consulting, distribution, and technical support. Implanet has also specialized in the development of software and medical devices specifically tailored to the needs of orthopedic surgeons and other medical professionals. For example, the PASS software enables digital planning and simulation of surgeries, thereby improving the accuracy and effectiveness of operations. Implanet also has a strong presence in Europe and the United States and continues to expand its market footprint. The company has formed strategic partnerships with leading manufacturers of orthopedic implants and instruments in Europe and the United States to ensure broader market coverage. Additionally, Implanet has an extensive network of distribution partners who globally distribute the company's products and services while providing premier service and consultation to customers. Implanet also offers its customers a comprehensive training program to educate them on how to make the best use of the company's products and services. This ensures that customers can fully benefit from the advantages of the products and services. Overall, Implanet SA provides a comprehensive solution for the treatment of spinal diseases. The company offers a wide range of products and services tailored to the needs of patients, physicians, and facilities, as well as an extensive network of partners and distributors who provide premier service and consultation.
The revenue cannot currently be calculated for Implanet.
The profit cannot currently be calculated for Implanet.
The P/E ratio cannot be calculated for Implanet at the moment.
The P/S cannot be calculated for Implanet currently.
The Eulerpool Quality Score for Implanet is 3/10.
The ISIN of Implanet is FR0013470168. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Implanet is A1W8RN. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Implanet is ALIMP.PA. The ticker symbol is used to trade Implanet shares on the stock exchange.
Implanet paid dividends every year for the past 0 years.
Implanet is assigned to the 'Health' sector.
The dividends of Implanet are distributed in EUR.
Implanet stock
Implanet Peer Group
Implanet Ticker
Implanet FIGI
All fundamentals and in-depth analysis of Implanet
Our stock analysis for Implanet stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Implanet. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.